BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 16:00:02 2024-07-05 EDT			5-day change	1st Jan Change
34.07 ^USD	+0.83%		-1.84%	-77.56%

05-31	Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing	MT
05-15	Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	MT

Biohaven Pharmaceuticals Signs Cody Ware as Driver for Nurtec® Odt Chevrolet for the 2021 NASCAR Cup Series Season

January 18, 2021 at 10:10 am

Biohaven Pharmaceuticals announced that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season. The first race of the season with Cody behind the wheel is the DAYTONA 500, at Daytona International Speedway on February 14.

Latest news about Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing	05-31	MT
Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	05-15	MT
Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing	05-14	MT
Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	05-10	MT
Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	04-25	MT
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	04-23	MT
UBS Adjusts Biohaven Price Target to $60 From $59, Maintains Buy Rating	04-23	MT
Biohaven Insider Bought Shares Worth $7,999,961, According to a Recent SEC Filing	04-23	MT
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing	04-23	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	04-18	MT
Biohaven Prices $230 Million Public Share Offering	04-18	MT
Biohaven Launches $200 Million Common Stock Offering	04-17	MT
HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating	03-04	MT
TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating	03-01	MT
RBC Trims Price Target on Biohaven to $61 From $62, Keeps Outperform, Speculative Risk	03-01	MT
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	02-29	MT
RBC Initiates Biohaven at Outperform With Speculative Risk, Sets Price Target at $62, Sees 'Significant Value to Be Unlocked' Over Long Term	02-16	MT
UBS Adjusts Initiates Biohaven Pharmaceutical Holding With Buy Rating, $59 Price Target	02-06	MT
Biohaven Insider Sold Shares Worth $459,663, According to a Recent SEC Filing	01-02	MT
Baird Starts Biohaven Pharmaceutical With Outperform Rating, $58 Price Target	12-08	MT
JPMorgan Adjusts Biohaven Pharmaceutical Price Target to $32 From $26, Maintains Overweight Rating	11-20	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $36 From $29, Keeps Overweight Rating	11-15	MT
Biohaven Pharmaceutical Q3 Net Loss Narrows	11-14	MT
Biohaven Pharmaceutical Says Obesity Treatment Candidate Reduces Fat, Improves Lean Mass	23-10-16	MT
Biohaven Insider Bought Shares Worth $9,999,990, According to a Recent SEC Filing	23-10-11	MT

Chart Biohaven Pharmaceutical Holding Company Ltd.

Duration

Period

Chart Biohaven Pharmaceutical Holding Company Ltd.

More charts

Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.	-77.56%	541M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research